MGC Pharmaceuticals (ASX:MXC) - Co Founder, CEO & Managing Director, Roby Zomer
Co Founder, CEO & Managing Director, Roby Zomer
Source: MGC Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) has been granted a patent from the Slovenian Intellectual Property Office (SIPO) for CimetrA
  • The patent provides MGC with commercial protection over the intellectual property regarding the formation and manufacturing process of CimetrA for a 20-year period
  • CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
  • MGC Pharma enters Friday trade with shares trading at 2.2 cents

MGC Pharmaceuticals (MXC) has been granted a patent from the Slovenian Intellectual Property Office (SIPO) for CimetrA.

The patent provides MGC Pharma with commercial protection over the intellectual property regarding the formation and manufacturing process of CimetrA for a 20-year period.

CimetrA is made up of artemisinin, a drug from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.

It is then mixed with vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.

It can come in either a solid or a liquid form and has antioxidant, anti-inflammatory and immuno-modulating properties.

“The grant of the patent by the Slovenian Intellectual Property Office is a key milestone for MGC Pharma, with the patent acknowledging the uniqueness of CimetrA’s formulation, as well as providing commercial protection of the intellectual property used to manufacture the product,” Co-Founder and Managing Director Roby Zomer said.

“The grant of the patent is a further step forward for MGC Pharma in its strategy to the development of a range of proprietary products, and becoming a wholly bio-pharma company with the ability to produce high-grade pharmaceutical products to the treat the symptoms of some of the most debilitating conditions.”

MGC Pharma enters Friday trade with shares trading at 2.2 cents.

MXC by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…